Who is sponsoring NCT03892330?

NCT03892330 is sponsored by Shengjing Hospital.

What drugs are being tested in NCT03892330?

Interventions in NCT03892330: Vincristine, Oxytetracycline/ Cyclophosphamide, Liposomal doxorubicin, Doxorubicin, Pharmorubicin, Pirarubicin.

What condition does NCT03892330 study?

NCT03892330 studies 0.5-14 Year Old Children With Nephroblastoma.

Is NCT03892330 still recruiting?

NCT03892330 is currently not yet recruiting. Last updated 27 March 2019.

Last reviewed 2019-03-27 · How we verify

NCT03892330

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Combination Therapy of Anthracyclines for Children With Nephroblastoma

Not yet recruiting Phase 4 Last updated 27 March 2019

What this trial tests

Phase 4 trial testing Vincristine in 0.5-14 Year Old Children With Nephroblastoma in 120 participants. Not yet recruiting.

Timeline

1 June 2019

Primary endpoint
31 December 2020

30 June 2045

Quick facts

Lead sponsor	Shengjing Hospital
Phase	Phase 4
Status	Not yet recruiting
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	120
Start date	1 June 2019
Primary completion	31 December 2020
Estimated completion	30 June 2045
Sites	1 location across China

Drugs / interventions tested

Vincristine (vincristine) — full drug profile →
Oxytetracycline/ Cyclophosphamide
Liposomal doxorubicin (liposomal-doxorubicin) — full drug profile →
Doxorubicin (doxorubicin) — full drug profile →
Pharmorubicin — full drug profile →
Pirarubicin (PIRARUBICIN) — full drug profile →

Conditions studied

0.5-14 Year Old Children With Nephroblastoma — all drugs for 0.5-14 Year Old Children With Nephroblastoma →

Sponsor

Shengjing Hospital

Who can join

Adults 6 Months to 14, any sex, with 0.5-14 Year Old Children With Nephroblastoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study aims to estimate the efficacy and side effects of study drugs in children with nephroblastoma who are treated with combination therapy.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Vincristine

Trials testing the same drug.

NCT07444710 — Testing the Addition of an Anti-Cancer Drug, Glofitamab, to the Usual Chemotherapy Treatment (Alternating R-CHOP/R-DHAP) · Phase 1 · not yet recruiting
NCT07387926 — Safety and Efficacy of Asciminib in Pediatrics and Young Adults With Relapse/Refractory (r/r) Philadelphia Positive (Ph+ · Phase 1, PHASE2 · not yet recruiting
NCT07133997 — Recombinant Erwinia Asparaginase and Venetoclax in Combination With Blinatumomab for the Treatment of Relapsed or Refrac · Phase 1 · recruiting
NCT06738368 — Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) With or Without Rituximab Plus Recombin · Phase 2 · recruiting
NCT07493148 — Chidamide Combination With R-mini CHOP Followed by Chidamide+CD20 Maintenance in Elderly Newly Diagnosed MYC/BCL2+ DLBCL · Phase 2 · recruiting

Other Shengjing Hospital trials

Trials by the same sponsor.

NCT07484763 — Predicting Recurrence in HR+/HER2- Early Breast Cancer · not yet recruiting
NCT07497191 — AMH Dynamic Changes to Predict Ovarian Reserve in Perimenopausal Breast Cancer · not yet recruiting
NCT07320599 — Neuroendoscopic Surgery With Ommaya Reservoir Implantation vs. Burr Hole Drainage for Infantile Postmeningitis Subdural · not yet recruiting
NCT07153783 — Interventional AI-Human Collaboration for Liver Tumor Diagnosis · NA · completed
NCT07101614 — A Randomized Study of JS004 and Toripalimab Combined With Chemotherapy vs Toripalimab Combined With Chemotherapy vs Chem · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03892330 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Shengjing Hospital
Last refreshed: 27 March 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03892330.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing